New trial aims to outsmart superbug in ICU patients
NCT ID NCT06440304
First seen Jan 27, 2026 · Last updated Jun 24, 2026 · Updated 19 times
Summary
This study tests three different antibiotic combinations to treat a dangerous, drug-resistant bacteria called CRAB that causes infections in intensive care patients. Researchers will compare colistin combined with either fosfomycin, ampicillin/sulbactam, or eravacycline in 108 surgical ICU patients. The goal is to find which combination clears the infection fastest and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS, BACTERIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Centre Zagreb
RECRUITINGZagreb, 10000, Croatia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colistin combined with either fosfomycin, ampicillin/sulbactam, or eravacycline
What this could lead to
If successful, this could identify the most effective antibiotic combination for treating drug-resistant CRAB infections in ICU patients, potentially improving survival and reducing hospital stays.
What could go wrong
This is a relatively small trial (108 participants) and results may not apply to all patients. Antibiotic resistance is complex, and even the best combination may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.